Survivin and IAP proteins in cell-death mechanisms

被引:300
作者
Altieri, Dario C. [1 ]
机构
[1] Univ Massachusetts, Sch Med, Prostate Canc Discovery & Dev Program, Dept Canc Biol, Worcester, MA 01605 USA
基金
美国国家卫生研究院;
关键词
cancer therapy; inhibitor of apoptosis (IAP); mitochondrion; nuclear factor kappa B (NF-kappa B); survivin; NF-KAPPA-B; X-LINKED INHIBITOR; ALPHA-DEPENDENT APOPTOSIS; STRUCTURAL BASIS; CANCER-CELLS; MICROTUBULE DYNAMICS; MEDIATED APOPTOSIS; MITOTIC REGULATOR; TUMOR SUPPRESSION; LIGASE ACTIVITY;
D O I
10.1042/BJ20100814
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
From the realization that cell number homoeostasis is fundamental to the biology of all metazoans, and that deregulation of this process leads to human diseases, enormous interest has been devoted over the last two decades to map the requirements of cell death and cell survival. This effort has led to tangible progress, and we can now chart with reasonable accuracy complex signalling circuitries controlling cell-fate decisions. Some of this knowledge has translated into novel therapeutics, and the outcome of these strategies, especially in cancer, is eagerly awaited. However, the function of cell-death modifiers have considerably broadened over the last few years, and these molecules are increasingly recognized as arbiters of cellular homoeostasis, from cell division, to intracellular signalling to cellular adaptation. This panoply of functions is best exemplified by members of the IAP (inhibitor of apoptosis) gene family, molecules originally narrowly defined as endogenous caspase inhibitors: but now firmly positioned at the crossroads of multiple normal and transformed cellular responses.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 104 条
  • [1] Opinion - Survivin, cancer networks and pathway-directed drug discovery
    Altieri, Dario C.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (01) : 61 - 70
  • [2] The case for survivin as a regulator of microtubule dynamics and cell-death decisions
    Altieri, Dario C.
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (06) : 609 - 615
  • [3] Validating survivin as a cancer therapeutic target
    Altieri, DC
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 46 - 54
  • [4] Degradation of survivin by the x-linked inhibitor of apoptosis (XIAP)-XAF1 complex
    Arora, Vinay
    Cheung, Herman H.
    Plenchette, Stephanie
    Micali, O. Cristina
    Liston, Peter
    Korneluk, Robert G.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (36) : 26202 - 26209
  • [5] Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity
    Barrett, Rachel M. A.
    Osborne, Toby P.
    Wheatley, Sally P.
    [J]. CELL CYCLE, 2009, 8 (02) : 278 - 283
  • [6] OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls
    Baud, Veronique
    Karin, Michael
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) : 33 - 40
  • [7] cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination
    Bertrand, Mathieu J. M.
    Milutinovic, Snezana
    Dickson, Kathleen M.
    Ho, Wai Chi
    Boudreault, Alain
    Durkin, Jon
    Gillard, John W.
    Jaquith, James B.
    Morris, Stephen J.
    Barker, Philip A.
    [J]. MOLECULAR CELL, 2008, 30 (06) : 689 - 700
  • [8] A Tangled Web of Ubiquitin Chains: Breaking News in TNF-R1 Signaling
    Bianchi, Katiuscia
    Meier, Pascal
    [J]. MOLECULAR CELL, 2009, 36 (05) : 736 - 742
  • [9] Mitochondria: pharmacological manipulation of cell death
    Bouchier-Hayes, L
    Lartigue, L
    Newmeyer, DD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) : 2640 - 2647
  • [10] The mitotic regulator survivin binds as a monomer to its functional interactor borealin
    Bourhis, Eric
    Hymowitz, Sarah G.
    Cochran, Andrea G.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (48) : 35018 - 35023